CA-PERSONALIS,-INC.
18.11.2020 14:02:04 CET | Business Wire | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia.
The company will showcase both their platforms, ImmunoID NeXT™ and NeXT Liquid Biopsy™.
ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample, thus maximizing the biological information that can be generated from a precious tumor specimen.
NeXT Liquid Biopsy , a first-of-its-kind, high-performance exome-wide liquid biopsy assay, provides a unique ability to evaluate the cancer ecosystem and advance the development of next-generation therapies. While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies has demonstrated there can be more to a cancer’s genotypic profile than that found in a single tissue biopsy. Therefore, the combination of NeXT Liquid Biopsy and ImmunoID NeXT delivers the most comprehensive view of a cancer’s mutational landscape by evaluating both the tissue and blood. NeXT Liquid Biopsy enables investigation into key applications such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. In this presentation, we’ll highlight data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of reference standards and patient samples.
Following are details for the Personalis presentations.
Scientific Poster Presentation
Poster Number |
Title & Presenter |
Dates |
||
40
|
Sensitive detection and monitoring of genetic alterations in circulating cfDNA with an enhanced whole-exome approach
|
NOV 18-19 | Online |
Following are details of an industry-sponsored symposium which will be presented at the meeting.
Satellite Symposia
Title |
Title & Presenter |
Dates |
||
Sponsored Symposia |
NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics
|
NOV 18-19 | On Demand |
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform ® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc ).
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the ImmunoID NeXT Platform, Personalis’ services for the VA MVP, the company’s business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including the company’s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005479/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Rock-It Company Expands Dynamic Dox to Provide ATA Carnet Services Across the US and Canada9.9.2026 17:00:00 CEST | Press release
Expansion provides access and expert ATA Carnet services for customers across new regions The Rock-It Company announced today the expansion of Dynamic Dox, the industry-leading provider of ATA Carnets, to now service partners and projects based in the United States, Canada and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909137375/en/ Following over a decade of expertise and leading service across the United Kingdom since 2014, Dynamic Dox will now provide new regions with dedicated document preparation for time-sensitive logistics projects, and urgent ATA Carnets for international shipments and critical business travel needs. The news of the expansion follows Dynamic Dox’s recent brand refresh, introducing an updated identity and connection to The Rock-It Company as Dynamic Dox By Rock-It. The expansion is led by Amanda Barlow, VP of Global ATA Carnets at The Rock-It Company, who has helped to drive the platfor
Ennov Appoints Oxana Pickeral as Chief Executive Officer9.9.2026 16:00:00 CEST | Press release
Ennov (the “Company”), a global provider of a unified compliance platform that streamlines regulatory, clinical, quality, and pharmacovigilance operations for life sciences and healthcare companies, today announced the appointment of Dr. Oxana Pickeral as Chief Executive Officer. Founder and outgoing CEO, Olivier Pâris, will join Ennov’s Board of Directors and continue to support the company as a Strategic Advisor. Dr. Pickeral has spent her career at the forefront of innovation in life sciences technology, from her early work on the Human Genome Project to growing Amazon Web Services’ Healthcare & Life Sciences partner business, enabling modern cloud solutions across the industry. She joins Ennov most recently from Honeywell, where she served as Global Software and Connected Life Sciences business leader, and previously as President and CEO of Sparta Systems, a Honeywell company. Across her leadership roles, she has successfully scaled global companies at the intersection of life scie
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors9.9.2026 15:45:00 CEST | Press release
- Recognized for the invention of a bispecific antibody that transformed treatment paradigm through an unconventional approach – Recognized for realizing a novel drug discovery concept in which a bispecific antibody replaces the function of coagulation Factor VIII, which is deficient in hemophilia A. Provided improved convenience through prolonged activity and subcutaneous administration, and provided a treatment option regardless of factor VIII inhibitors, thereby helping address unmet medical needs in hemophilia A. First time since the establishment of the Lasker Foundation in 1945 that three Japanese researchers have received the award simultaneously. Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), who led the creation of Hemlibra (emicizumab), a treatment for hemophilia A, have been aw
AMCS Appoints Richard Humphrey as Chief Product and Technology Officer9.9.2026 15:00:00 CEST | Press release
Industrial software executive to lead global product strategy and accelerate AI innovation AMCS, a leading technology provider for the waste and recycling industry, today announced the appointment of Richard Humphrey as Chief Product and Technology Officer. Based in Boston, Humphrey will lead the company’s global product organisation. Humphrey brings more than 25 years of experience developing software for construction and other complex industrial environments. He joins AMCS as the company deepens its focus on waste and recycling and expands the role of AI across its platform. Most recently, Humphrey served as Chief Product and Technology Officer at Contruent, where he led product strategy for a construction cost-management platform used on major capital programmes. He previously held vice president roles at Bentley Systems and B2W Software. Earlier in his career, he spent more than a decade at Autodesk, where he led its Civil Design and Construction software business as Senior Directo
BBH Launches a New Technology Business, Braid, Solving for Intelligent Data Transformation9.9.2026 14:45:00 CEST | Press release
Braid’s agentic AI platform is purpose-built for financial services firms who need to transform, connect, and manage their data with confidence Brown Brothers Harriman (BBH) today announced the launch of a new technology affiliate, Braid LLC, focused on solving enterprise data transformation for financial services. Braid offers an AI-native data transformation platform that gives firms a scale solution to transform, connect, and manage their data with confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909294398/en/ Braid empowers teams to build, automate, and oversee reliable production-grade data transformations in a fraction of the time typically required today. Instead of requiring engineers to build data automations, Braid allows business users to describe their needs in natural language that AI agents use to build intelligent data transformations that are transparent and fully auditable. Braid’s enterprise-gr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom